FTC Clears Caremark/AdvancePCS Deal, Expects Regional PBMs To Serve Small Employers
This article was originally published in The Pink Sheet Daily
The merger’s completion awaits shareholder approval by both companies, which is expected to occur before the end of March. The combined firm is likely to have increased bargaining power that can be passed on to customers, FTC says.
You may also be interested in...
AdvancePCS and ABC agree to extend their contract until Sept. 30; Caremark's acquisition of AdvancePCS is expected to close in March. ABC remains pessimistic about retaining the contract beyond September.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
Three FDA risk management final guidances recommend that sponsors collect a wide range of safety data during both the clinical trial and postmarketing periods of drug development. The agency suggests that sponsors hold discussions with FDA before settling on drug study designs or postmarketing activities.